Center for Regenerative and Personalized Medicine, Steadman Philippon Research Institute, Vail, CO, USA; Department of Orthopaedic Surgery, Kobe University Graduate School of Medicine, Kobe, Japan.
Center for Regenerative and Personalized Medicine, Steadman Philippon Research Institute, Vail, CO, USA.
Pharmacol Res. 2022 Nov;185:106504. doi: 10.1016/j.phrs.2022.106504. Epub 2022 Oct 13.
As the worldwide population progresses in age, there is an increasing need for effective treatments for age-associated musculoskeletal conditions such as osteoporosis and osteoarthritis (OA). Fisetin, a natural flavonoid, has garnered attention as a promising pharmaceutical option for treating or delaying the progression of osteoporosis and OA. However, there is no systematic review of the effects of fisetin on bone and cartilage. The aim of this review is to report the latest evidence on the effects of fisetin on bone and cartilage, with a focus on clinical significance. The PubMed, Embase, and Cochrane Library databases were searched up to December 9th 2021 to evaluate the effects of fisetin on bone and cartilage in in vitro studies and in vivo preclinical animal studies. The risk of bias, quality, study design, sample characteristics, dose and duration of fisetin treatment, and outcomes of the 13 eligible studies were analyzed in this systematic review. Qualitative evaluation was conducted for each study due to differences in animal species, cell type, created disease model, dose and duration of fisetin treatment, and time between intervention and assessment among the eligible studies. The beneficial effects of fisetin on osteoporosis have been demonstrated in in vitro and in vivo preclinical studies across animal species. Similarly, the beneficial effects of fisetin on OA have been demonstrated in in vivo preclinical animal studies, but the reports on OA are still limited. Fisetin, a natural supplement can be use in orthobiologics treatment, as adjuvant to orthopaedic surgery, to improve clinical outcome.
随着全球人口老龄化，人们越来越需要有效的治疗方法来治疗与年龄相关的肌肉骨骼疾病，如骨质疏松症和骨关节炎（OA）。漆黄素是一种天然类黄酮，作为治疗或延缓骨质疏松症和 OA 进展的有前途的药物选择引起了关注。然而，目前尚无关于漆黄素对骨骼和软骨影响的系统评价。本综述的目的是报告最新的关于漆黄素对骨骼和软骨影响的证据，重点关注临床意义。截至 2021 年 12 月 9 日，我们在 PubMed、Embase 和 Cochrane Library 数据库中进行了检索，以评估在体外研究和体内临床前动物研究中漆黄素对骨骼和软骨的影响。本系统评价分析了 13 项合格研究的偏倚风险、质量、研究设计、样本特征、漆黄素治疗的剂量和持续时间以及结果。由于合格研究中动物种类、细胞类型、所创建的疾病模型、漆黄素治疗的剂量和持续时间以及干预和评估之间的时间不同，对每项研究都进行了定性评估。在不同的动物物种中，在体外和体内临床前研究中都证明了漆黄素对骨质疏松症的有益影响。同样，在体内临床前动物研究中也证明了漆黄素对 OA 的有益影响，但关于 OA 的报道仍然有限。漆黄素作为一种天然补充剂，可以用于骨科生物治疗，作为骨科手术的辅助手段，以改善临床结果。
